Connect with us

Hi, what are you looking for?


Cannabis Firm Reports Results of First Trial For Cannabinoid-Based Sleep Medicine

Zelira Therapeutics say that the first results of a clinical trial for a cannabinoid-based insomnia medication are promising.

Cannabis Firm Reports Results of First Trial For Cannabinoid-Based Sleep Medicine

An Australian medical cannabis company is trumpeting the results of a clinical trial for its insomnia treatment.

Zelira Therapeutics said last week that it received the final report for its proprietary cannabis formulation known as ZTL-101, and that its findings “represent a world-first clinical” validation of the treatment as being safe and effective in combating chronic insomnia.

Those findings, Zelira said, “open prospects to launch and distribute this product in global markets including the USA in the second half of 2020.”

Zelira said the trial was conducted at the University of Western Australia (UWA) Centre for Sleep Science, where researchers used a randomized, double-blind, cross-over design to evaluate ZTL-101’s effectiveness.

“Twenty three patients were treated for 14 nights with ZTL-101 and 14 nights with placebo, separated by a one-week washout period,” Zelira said in a press release. “After dosing commenced, each participant was able to take a single (0.5ml of 11.5mg total cannabinoids) or double (1 ml of 23mg total cannabinoids) their dose of the medication, delivered sublingually, according to their symptoms.”

Promising First Results

According to Zelira, the analysis “showed treated patients slept significantly longer, went to sleep faster and went back to sleep sooner after waking,” while those same patients “also reported significant improvement in quality of life measures including feeling rested after sleep, feeling less stressed, less fatigued and improved overall functioning.”

Peter Eastwood, the principal researcher in the trial and a professor at the University of Western Australia Centre for Sleep Science, called it “the most rigorous clinical trial ever undertaken to assess the therapeutic potential of medicinal cannabis to treat the symptoms of chronic insomnia.”

“The fact that ZLT-101 treatment achieved statistically significant, dose responsive improvements across a broad range of key insomnia indices is impressive, particularly given the relatively short two-week dosing window,” Eastwood said in a statement. 

Zelira has headquarters in both Perth and Philadelphia.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *


HT Newsletter

Subscribe for exclusive access to deals, free giveaways and more!

Thank you for subscribing.

Something went wrong.


You May Also Like


Experts say that the lack of clarity and provisions will allow the illicit market to continue to thrive.


Climate change is fueling Australia's worsening fire season, but authorities are blaming individual arsonists for starting the fires.


Las investigaciones evaluarán la efectividad de CogniCann, un aerosol de cannabis oral patentado, como un tratamiento para la agresión y agitación causadas por la...


The laws take effect on January 31, 2020.


A well-rounded cannabinoid routine can support your health and general wellness.


They also rejected opioid use disorder and insomnia.


As part of a series titled "Shelf Medication," DENIAL created a giant High Times-branded pill capsule symbolizing medicine's growing embrace of cannabis.


Pending a recommendation, the Ohio medical board will vote June 12 to add insomnia, depression, anxiety, autism spectrum disorder and opioid use disorder to...

Do NOT follow this link or you will be banned from the site!